Articles

Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia

The Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA;University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA
University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA
The Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
Mayo Clinic, Rochester, MN, USA
The Blood and Marrow Transplant Program at Northside Hospital, Bone Marrow Transplant Group of Georgia, Atlanta, GA, USA
Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
Virginia Commonwealth University, Massey Cancer Center, Richmond, VA, USA
Texas Oncology, Baylor Charles A. Simmons Cancer Center, Dallas, TX, USA
Mayo Clinic, Scottsdale, AZ, USA
The Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA;University of Maryland Medical Center, Stewart Greenebaum Cancer Center, Baltimore, MD, USA
The Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
The Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
National Cancer Institute, Rockville, MD, USA
National Cancer Institute, Rockville, MD, USA
National Cancer Institute, Rockville, MD, USA
The Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
The Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
Vol. 100 No. 9 (2015): September, 2015 https://doi.org/10.3324/haematol.2015.125849